CRIMINAL LAWAND PROCEDURE
319
moderate or low physical dependence or
high psychological dependence.
(b) The board may recommend placement of
a substance in schedule III under this chapter if it
finds that the substance is classified as a con-
trolled substance in schedule III under federal
law.
35-48-2-8. Schedule III.
(a) The controlled substances listed in this
section are included in schedule III.
(b) Stimulants. Unless specifically excepted or
unless listed in another schedule, any material,
compound, mixture, or preparation which contains
any quantity of the following substances having
a stimulant effect on the central nervous system,
including its salts, isomers (whether optical, posi-
tion, or geometric), and salts of such isomers
whenever the existence of such salts, isomers,
and salts of isomers is possible within the specific
chemical designation:
(1) Those compounds, mixtures, or prepa-
rations in dosage unit form containing any
stimulant substances listed in schedule II
which compounds, mixtures, or prepara-
tions were listed on April 1, 1986, as
excepted compounds under 21 CFR
1308.32, and any other drug of the quan-
titative composition shown in that list for
those drugs or that is the same except that
it contains a lesser quantity of controlled
substances (1405).
(2) Benzphetamine (1228).
(3) Chlorphentermine (1645).
(4) Clortermine (1647).
(5) Phendimetrazine (1615).
(c) Depressants. Unless specifically excepted
or unless listed in another schedule, any material,
compound, mixture, or preparation which contains
any quantity of the following substances having
a depressant effect on the central nervous sys-
tem:
(1) Any compound, mixture, or preparation
containing:
(A)amobarbital (2126);
(B) secobarbital (2316);
(C) pentobarbital (2271); or
(D)any of their salts;
and one (1) or more other active medici-
nal ingredients which are not listed in any
schedule.
(2) Any suppository dosage form con-
taining:
(A)amobarbital (2126);
(B) secobarbital (2316);
(C) pentobarbital (2271); or
(D)any of their salts;
and approved by the Food and Drug
Administration for marketing only as a
suppository.
(3) Any substance which contains any
quantity of a derivative of barbituric acid,
or any salt thereof (2100).
(4) Chlorhexadol (2510).
(5) Embutramide (2020).
(6) Lysergic acid (7300).
(7) Lysergic acid amide (7310).
(8) Methyprylon (2575).
(9) Sulfondiethylmethane (2600).
(10) Sulfonethylmethane (2605).
(11) Sulfonmethane (2610).
(12) A combination product containing
Tiletamine and Zolazepam or any salt
thereof (Telazol) (7295).
(13) Any drug product containing gamma-
hydroxybutyric acid, including its salts,
isomers, and salts of isomers, for which an
application is approved under section 505
of the federal Food, Drug and Cosmetic
Act, 21 U.S.C. 301 et seq. (2012).
(d) Nalorphine (a narcotic drug) (9400).
(e) Narcotic Drugs. Unless specifically
excepted or unless listed in another schedule, any
material, compound, mixture, or preparation con-
taining any of the following narcotic drugs, or their
salts calculated as the free anhydrous base or
alkaloid, in the following limited quantities:
(1) Not more than 1.8 grams of codeine,
per 100 milliliters or not more than 90
milligrams per dosage unit, with an equal
or greater quantity of an isoquinoline alka-
loid of opium (9803).
(2) Not more than 1.8 grams of codeine,
per 100 milliliters or not more than 90
milligrams per dosage unit, with one (1) or
more active, nonnarcotic ingredients in
recognized therapeutic amounts (9804).
(3) Not more than 300 milligrams of dihy-
